ConductScience.org, home

Paper96213

The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects.

Stephens MC and 4 others. J Neurochem, 1978. Cited by 42 papers, by iCite.

Cite this record

ConductScience Library. The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects. Papers, record 96213. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/96213

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects.
PubMed
Journal
J Neurochem
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
42
iCite
Relative citation ratio, by iCite
1.15
iCite
Revised in PubMed
2019-12-10
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stephens MCM C
2Bernatsky AA
3Burachinsky VV
4Legler GG
5Kanfer JNJ N

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Gaucher DiseaseMajor topic
InositolMajor topic
Acetylglucosaminidase
Animals
Brain
Cerebrosides
Humans
Liver
Male
Mice
Spleen
beta-Glucosidase

Source PubMed

Download CSV of topics

Cited by16

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.

PMIDTitleJournalYearIn PapersSource
41559755Constraint-based modelling of metabolic dysregulation in Gaucher disease: mitochondrial dysfunction and disrupted cholesterol homeostasis.Orphanet J Rare Dis2026https://conductscience.org/library/papers/41559755PubMed
41465340Refining Mouse Models of Gaucher Disease: Advancing Mechanistic Insights, Biomarker Discovery, and Therapeutic Strategies.Int J Mol Sci2025https://conductscience.org/library/papers/41465340PubMed
38003227Animal Models for the Study of Gaucher Disease.Int J Mol Sci2023https://conductscience.org/library/papers/38003227PubMed
37014126Glycosphingolipids within membrane contact sites influence their function as signaling hubs in neurodegenerative diseases.FEBS Open Bio2023https://conductscience.org/library/papers/37014126PubMed
30279220Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.J Lipid Res2018https://conductscience.org/library/papers/30279220PubMed
28701774Inhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis.Sci Rep2017https://conductscience.org/library/papers/28701774PubMed
28430167Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned?Int J Mol Sci2017https://conductscience.org/library/papers/28430167PubMed
26948439CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.Mol Ther2016https://conductscience.org/library/papers/26948439PubMed
23880767β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.J Biol Chem2013https://conductscience.org/library/papers/23880767PubMed
21954067Animal models for Gaucher disease research.Dis Model Mech2011https://conductscience.org/library/papers/21954067PubMed
15669681Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.J Inherit Metab Dis2004https://conductscience.org/library/papers/15669681PubMed
8473508Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function.J Clin Invest1993https://conductscience.org/library/papers/8473508PubMed
8163674Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease.J Clin Invest1994https://conductscience.org/library/papers/8163674PubMed
6517862Characterization of the phospholipid requirement of a rat liver beta-glucosidase.Biochem J1984https://conductscience.org/library/papers/6517862PubMed
3099116Glucosylceramide and the level of the glucosidase-stimulating proteins.Lipids1986https://conductscience.org/library/papers/3099116PubMed
290986L-glucosylceramide: synthesis, properties, and resistance to catabolism by glucocerebrosidase in vitro.Proc Natl Acad Sci U S A1979https://conductscience.org/library/papers/290986PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/96213

GET https://conductscience.org/api/papers/v1/96213/authors